17+ hour, 17+ min ago  (118+ words) Q2 2026 pre-close call covered macroeconomic trends, P&L expectations, and capital updates. Focus remains on organic growth, with openness to M&A in Sweden, though no deals are currently active. Private lending grew 3% year-over-year, corporate lending up 6% year-over-year. Net interest income…...

3+ day, 1+ hour ago  (257+ words) SSG (Software, Services, and Growth) now represents 17% of business, with rapid expansion across India, META, and SESA, and a focus on recurring, predictable revenue streams. Ranked #8 globally and #1 in India and MEA among technology distributors, with $13. 4 B in reported revenue....

1+ week, 4+ day ago  (193+ words) Every earnings call, transcript, and filing from 15, 000+ public companies. Now queryable directly in Perplexity Computer. NEW YORK & STOCKHOLM " Through a native MCP integration, Quartr's structured, first-party IR data is now available in Perplexity Computer. Live and recorded earnings calls, real-time…...

1+ mon, 1+ week ago  (397+ words) Achieved double-digit streaming revenue growth and robust free cash flow in Q1 2026, with improved advertising revenue trends and expanded distribution partnerships, including new content launches and original series. Revenues for Q1 2026 were $542. 1 million, down 2. 4% year-over-year, with operating income dropping 51% to $31 million and…...

1+ mon, 3+ week ago  (215+ words) First clinical data for base editing technology in sickle cell disease shows high efficacy, with BEAM-101 achieving mid-60s fetal hemoglobin and significant reduction in sickle protein, indicating a potentially best-in-class profile. Uniform and deep gene editing achieved, with over 90% of cells…...

4+ mon, 2+ week ago  (162+ words) The platform's programmability allows rapid expansion to new targets, reducing risk and investment for subsequent programs. Clinical proof of concept in both ex vivo and in vivo settings validates the platform's repeatability and scalability. BEAM-101 upregulates fetal hemoglobin via precise…...

3+ mon, 3+ week ago  (304+ words) Announced expansion of the liver-targeted portfolio with BEAM-304, a new base editing program for PKU, targeting the two most common mutations and aiming to address a majority of PKU patients over time, with IND filing anticipated in 2026. Provided updates on…...

5+ mon, 3+ day ago  (221+ words) Reported first clinical data from one-time gene editing treatments, focusing on hematology (sickle cell disease) and liver genetic diseases (AATD), with BEAM-101 and BEAM-302 advancing in clinical trials. Four abstracts, including initial BEAM-101 clinical data and BEAM-201 oncology data, accepted…...

1+ mon, 3+ week ago  (219+ words) Q1 2026 revenues were $968. 3 million, flat year-over-year and within guidance. Net income declined to $5. 5 million from $20. 9 million in Q1 2025. Adjusted EBITDA was $83. 6 million (8. 6% margin), down from $93. 6 million (9. 7%) year-over-year. The company is rebranding to Everforth, unifying brands and updating segment reporting. Acquisition of Quinnox…...

2+ mon, 5+ day ago  (194+ words) Annual Meeting scheduled for May 18, 2026, with four key proposals for shareholder action, including director elections, executive compensation, incentive plan amendment, and auditor ratification. Shareholders of record as of April 6, 2026, are eligible to vote; multiple voting methods are available. The company…...